Compared to baseline (day 0), serum levels of sCD163 at day 42 were significantly increased in the group showing objective response (p < 0.0001; Figure 1A) among patients with advanced cutaneous melanoma, whereas no significant difference in serum sCD163 levels was seen among patients with advanced mucosal melanoma (Figure 2A). The gene discussed is CD163; the disease is mucosal melanoma.